Pfizer (PFE)
(Delayed Data from NYSE)
$29.50 USD
+0.19 (0.65%)
Updated Sep 24, 2024 04:01 PM ET
After-Market: $29.52 +0.02 (0.07%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.50 USD
+0.19 (0.65%)
Updated Sep 24, 2024 04:01 PM ET
After-Market: $29.52 +0.02 (0.07%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum D VGM
Zacks News
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
by Zacks Equity Research
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Top Stock Reports for Coca-Cola, Chevron & ServiceNow
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Chevron Corporation (CVX) and ServiceNow, Inc. (NOW), as well as two micro-cap stocks Sypris Solutions, Inc. (SYPR) and Mobile Infrastructure Corporation (BEEP).
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
by Zacks Equity Research
The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.
Here's Why Pfizer (PFE) Fell More Than Broader Market
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $29.42, denoting a -0.83% change from the preceding trading day.
Roche Antiviral Drug Reduces Transmission in Late-stage Study
by Zacks Equity Research
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
by Kinjel Shah
PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
by Zacks Equity Research
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
by Zacks Equity Research
The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
by Zacks Equity Research
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
by Zacks Equity Research
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
Lilly Gets FDA Approval for Eczema Drug Ebglyss
by Zacks Equity Research
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
by Andrew Rocco
Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
by Nalak Das
Three large-cap stocks ??? AES, PFE and UNM ??? currently offer attractive short-term returns along with a high dividend rate.
5 Bargain Price-to-Sales Stocks With High Growth Prospects
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GIII, BTU, HG, BBSI and PFE hold promise.
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
by Zacks Equity Research
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
Pfizer (PFE) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PFE or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Why Pfizer (PFE) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, Pfizer (PFE) closed at $29.74, indicating a +1.11% shift from the previous trading day.
Relay Stock Soars on Upbeat Data From Breast Cancer Study
by Zacks Equity Research
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.